Neutropenia: State of the knowledge Part II

Oncology Nursing Forum

Volumn 33, Issue 6, 2006, Pages 1202-1208

  Nirenberg, Anita ^a   Bush, Annette Parry ^b   Davis, Arlene ^c   Friese, Christopher R ^d,e   Gillespie, Theresa Wicklin ^f,g   Rice, Robert David ^h  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ONCOLOGY NURSING SOCIETY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ATLANTA VA MEDICAL CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ATTITUDE TO HEALTH; CHEMICALLY INDUCED DISORDER; HUMAN; METHODOLOGY; NEOPLASM; NEUTROPENIA; NURSING; ONCOLOGY NURSING; PATIENT CARE PLANNING; REVIEW;

ANTINEOPLASTIC AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NEOPLASMS; NEUTROPENIA; ONCOLOGIC NURSING; PATIENT CARE PLANNING;

EID: 34249060621     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/06.ONF.1202-1208     Document Type: Article

References (56)

1. American Cancer Society & National Comprehensive Cancer Network. (2006). Fever and neutropenia: Treatment guidelines for patients with cancer (version VII). Retrieved June 7, 2006, from http://www.nccn.org/ patients/patient_gls/_english/pdf/NCCN%20FN%20Guidelines.pdf
2. American Society of Clinical Oncology. (2006). ASCO patient guide: White blood cell growth factors. Retrieved May 21,2006, from http://www.plwc .org/portal/site/PLWC/menuitem.l69f5d85214941ccfd748f68ee37a01d/ ?vgnextoid=e2215adc8851b010VgnVCM100000ed730adlRCRD
3. Bodey, G.P. (2000). Fever in the neutropenic patient. In M.D. Abeloff, J.O. Armitage, A.S. Lichter, & J.E. Niederhuber (Eds.), Clinical oncology (2nd ed., pp. 690-706). New York: Churchill Livingstone.
4. Bonadonna, G., Valagussa, P., Molitemi, A., Zambetti, M., & Brambilla, C. (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. New England Journal of Medicine, 332, 901-906.
5. Boyce, J.M., & Pittet, D. (2002). Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infection Control and Hospital Epidemiology, 23(Suppl. 12), S3-S40.
6. Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M.S., Martinelli, G., et al. (2005). Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine, 353, 977-987.
7. Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute, 90, 1205-1211.
8. Byme, D.J., Napier, A., Phillips, G., & Cuschieri, A. (1991). Effects of whole body disinfection on skin flora in patients undergoing elective surgery. Journal of Hospital Infection, 17, 217-222.
9. Calhoun, E.A., Chang, C.H., Welshman, E.E., & Cella, D. (2003). The impact of chemotherapy delays on quality of life in patients with cancer [Abstract 2763]. Blood, 102, 749a.
10. Carter, L.W. (1994). Bacterial translocation: Nursing implications in the care of patients with neutropenia. Oncology Nursing Forum, 21, 857-865.
11. Cella, D., Chang, C.H., Lai, J.S., & Webster, K. (2002). Advances in quality of life measurements in oncology patients. Seminars in Oncology, 29(3, Suppl. 8), 60-68.
12. Crawford, J., Dale, D.C., & Lyman, G.H. (2004). Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer, 100, 228-237.
13. Cruciani, M., Rampazzo, R., Malena, M., Lazzarini, L., Todeschini, G., Messori, A., et al. (1996). Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clinical InfectiousDiseases, 23, 795-805.
14. Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P.,et al. (2005). Antibacterial prophylaxis after chemotherapy for solid tumorsand lymphomas. New England Journal of Medicine, 353, 988-998.
15. DeMille, D., Deming, P., Lupinacci, P., & Jacobs, L.A. (2006). The effectof the neutropenic diet in the outpatient setting: A pilot study. Oncology Nursing Forum, 33. 337-343.
16. Donohue, R. (2006). Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncology Nursing Forum,33, 347-352.
17. Duncan, S.L. (2000). APIC state-of-the-art report: The implications of service animals in health care settings. American Journal of Infection Control, 28, 170-180.
18. Erder, M.H., Fridman, M., & Weaver, C. (2001). Cancer patients' (CPs') perspectives about the impact of febrile neutropenia morbidity (FNM) on their well-being (WB) and preferences for filgrastim treatment versus dose reduction to prevent FN: An Internet survey [Abstract 2589]. Proceedings of the American Society of Clinical Oncology, 20, 210b.
19. Fortner, B.V., Tauer, K.W., Okon, T., Houts, A.C., & Schwartzberg, L.S.(2005). Experiencing neutropenia: Quality-of-life interviews with adultcancer patients. BMC Nursing, 4, 4.
20. Former, B.V., Tauer, K.W., Zhu, L., Okon, T.A., Moore, K., Templeton, D.,et al. (2004). Medical visits for chemotherapy and chemotherapy-induced neutropenia: A survey of the impact on patient time and activities. BMC Cancer, 4(1), 22.
21. Gafter-Gvili, A., Fŕaser, A., Paul, M., & Leibovici, L. (2005). Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of Internal Medicine, 142(12, Pt. 1), 979-995.
22. Ganz, P.A., Lee, J.J., & Siau, J. (1991). Quality-of-life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 67, 3131-3135.
23. Garcia, R., Raad, I., Abi-Said, D., Bodey, G., Champlin, R., Tarrand, J., et al. (1997). Nosocomial respiratory syncytial virus infections: Prevention and control in bone marrow transplant patients. Infection Control and Hospital Epidemiology, 18, 412-416.
24. Gillespie, T.W. (2001). Chemotherapy dose and dose intensity: Analyzingdata to guide therapeutic decisions. Oncology Nursing Forum, 28(2, Suppl.), 5-10.
25. Given, B.A., Given, C.W., Jeon, S., & Sikorskii, A. (2005). Effect of neutropenia on the impact of a cognitive-behavioral intervention for symptom management. Cancer, 104, 869-878.
26. Given, B.A., & Sherwood, P.R. (2005). Nursing-sensitive patient outcomesA white paper. Oncology Nursing Forum, 32, 773-784.
27. Glaspy, J., Hackett, J., Flyer, P., Dunford, D., & Liang, B. (2001). Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities [Abstract 1812]. Blood, 98, 432a.
28. Hughes, W.T., Armstrong, D., Bodey, O.P., Bow, E.J., Brown, A.E., Calandra, T., et al. (2002). 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases, 34, 730-752.
29. Kates, S.G., McGinley, K.J., Larson, E.L., & Leyden, J.J. (1991). Indigenous multiresistant bacteria from flowers in hospital and nonhospital environments. American Journal of Infection Control, 19, 156-161.
30. Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
31. Larson, E. (2001). Hygiene of the skin: When is clean too clean? Emerging Infectious Diseases, 7, 225-230.
32. Larson, E., & Nirenberg, A. (2004). Evidence-based nursing practice to prevent infection in hospitalized neutropenic patients with cancer. Oncology Nursing Forum, 31, 717-723.
33. Lipscomb, J., Donaldson, M.S., & Hiatt, R.A. (2004). Cancer outcomes research and the arenas of application. Journal of the National Cancer Institute Monographs, 33, 1-7.
34. Lyman, G.H., Dale, D.C., & Crawford, J. (2003). Incidence and predictors of low dose-intensity adjuvant breast cancer chemotherapy: A nationwide study of community practices. Journal of Clinical Oncology, 21, 4524-4531.
35. Lyman, G.H., & Kuderer, N.M. (2002). Filgrastim in patients with neutropenia: Potential effects on quality of life. Drugs, 62(Suppl. 1), 65-78.
36. Martin, M., Lluch, M.A., Segui, A., Anton, A., Ruiz, M., Ramos, A., et al. (2004). Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 Study [Abstract 620]. Journal of Clinical Oncology, 22(14, Suppl.), 620.
37. Mitchell, S., Friese, C.R., & Beck, S.L. (2006). Putting evidence into practice: Ranking criteria for nursing interventions. Retrieved June 1, 2006, from http://www.ons.org/outcomes
38. Moody, K., Finlay, J., Mancuso, C., & Charlson, M. (2006). Feasibility and safety of a pilot randomized trial of infection rate: Neutropenic diet versus standard food safety guidelines. Journal of Pédiatrie Hematology/Oncology, 28(3), 126-133.
39. National Comprehensive Cancer Network. (2005). Clinical practice guidelines in oncology: Fever and neutropenia. Retrieved September 21,2005, fromhttp://www.nccn.org/professionals/physician_gls/PDF/fever.pdf
40. National Comprehensive Cancer Network. (2006). Clinical practice guidelines in oncology: Myeloid growth factors. Retrieved June 20,2006, from http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth .pdf
41. National Institutes of Health. (2005). Computerized retrieval of information on scientific projects. Retrieved August 15, 2005, from http://crisp.cit.nih.gov
42. Neugut, A.I., Matasar, M., Wang, X., McBride, R., Jacobson, J.S., Tsai, W.Y., et al. (2006). Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. Journal of Clinical Oncology, 24, 2368-2375.
43. Okon, T.A., Fortner, B.V., Schwartzberg, L., Tauer, K.T., Durrence, H., Kovacs, A., et al. (2002). Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN) [Abstract 2920]. Proceedings of the American Society of Clinical Oncology, 21, 275b.
44. Pizzo, P.A. (1999). Fever in immunocompromised patients. New England Journal of Medicine, 341, 893-900.
45. Raad, I., Abbas, J., & Whimbey, E. (1997). Infection control of nosocomial respiratory viral disease in the immunocompromised host. American Journal of Medicine, 102(3A), 48-52.
46. Rubenstein, E.B., Peterson, D.E., Schubert, M., Keefe, D., McGuire, D., Epstein, J., et al. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 100(9, Suppl.), 2026-2046.
47. Sehulster, L., & Chinn, R.Y. (2003). Guidelines for environmental infection control in health-care facilities: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morbidity and Mortality Weekly Report: Recommendations and Reports, 52(RR-10), 1-42.
48. Seidman, A.D., Portenoy, R., Yao, T.J., Lepore, J., Mont, E.K., Kortmansky, J., et al. (1995). Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. Journal of the National Cancer Institute, 87, 1316-1322.
49. Sickles, E.A., Greene, W.Y., & Wiemik, P.H. (1975). Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine, 135, 715-719.
50. Smith, C.M., & Kagan, S.H. (2005). Prevention of systemic mycoses by reducing exposure to fungal pathogens in hospitalized and ambulatory neutropenic patients. Oncology Nursing Forum, 32, 565-579.
51. Smith, L.H., & Besser, S.G. (2000). Dietary restrictions for patients with neutropenia: A survey of institutional practices. Oncology Nursing Forum, 27, 515-520.
52. von Minckwitz, G., Blohmer, J.U., Lohr, A., Raab, G., Eidtmann, H., Gerber, B., et al. (2005). Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide in breast cancer patients [Abstract]. Journal of Clinical Oncology, 23(Suppl. 16), 8008.
53. Wellness Community, (n.d.). Managing symptoms and side effects: Managing the side effects of cancer treatment. Retrieved May 13, 2006, from http://www.thewellnesscommunity.org/programs/frankly/treatment/ managing/managing.htm
54. Wilson, B.J. (2002). Dietary recommendations for neutropenic patients. Seminars in Oncology Nursing, 18, 44-49.
55. Wivell, B., & Fink, R. (2003, May). Neutropenic precautions: A journey to the development of evidence based standards. Poster presented at the Oncology Nursing Society 28th Annual Congress, Denver, CO.
56. Zitella, L., Friese, C.R., Hauser, J., Gobel, B.H., Woolery-Antil, M., O'Leary, C., et al. (in press). Putting evidence into practice: Prevention of infection. Clinical Journal of Oncology Nursing.